Zevra Therapeutics/$ZVRA
1D1W1MYTD1Y5YMAX
Capital at risk
About Zevra Therapeutics
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
- Ticker
- $ZVRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 61
- Headquarters
- Boston, United States
- Website
- www.zevra.com
ZVRA Metrics
BasicAdvanced
$593M
11.33
$0.88
0.95
-
Price and volume
Market cap
$593M
Beta
0.95
52-week high
$15.04
52-week low
$8.01
Average daily volume
915K
Financial strength
Current ratio
5.167
Quick ratio
5.018
Long term debt to equity
0.004
Total debt to equity
0.007
Interest coverage (TTM)
6.84%
Profitability
EBITDA (TTM)
40.553
Gross margin (TTM)
95.46%
Net profit margin (TTM)
42.82%
Operating margin (TTM)
28.71%
Effective tax rate (TTM)
15.91%
Revenue per employee (TTM)
$2,230,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
34.80%
Valuation
Price to earnings (TTM)
11.328
Price to revenue (TTM)
4.22
Price to book
2.68
Price to tangible book (TTM)
2.81
Price to free cash flow (TTM)
17.602
Free cash flow yield (TTM)
5.68%
Free cash flow per share (TTM)
0.568
Growth
Revenue change (TTM)
119.40%
Earnings per share change (TTM)
-1,355.30%
3-year revenue growth (CAGR)
101.86%
3-year earnings per share growth (CAGR)
22.06%
10-year earnings per share growth (CAGR)
-34.24%
What the Analysts think about ZVRA
Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.
Analyst projections of the future price of Zevra Therapeutics stock.
Bulls say / Bears say
MIPLYFFA is showing strong US commercial momentum: second-quarter revenue reached $30.2 million, up 40% year on year, while total revenue rose 53% to $39.7 million. Zevra also held $260.2 million in cash and investments, giving it room to fund growth without relying on near-term capital markets. (GlobeNewswire)
The MIPLYFFA evidence base is becoming broader and more durable. Four-year real-world data and a paediatric study in infants reported no new safety signals and support the case for early, long-term treatment, which could help physician adoption and future regulatory discussions. (GlobeNewswire, GlobeNewswire)
There are two meaningful upside catalysts beyond the current US launch. Zevra is seeking European approval again after a re-examination, while its Phase 3 celiprolol programme had enrolled 66 patients and is being discussed with the FDA for ways to accelerate development. (BioSpace, GlobeNewswire)
Europe is currently a setback, not an assured growth market. The EMA’s CHMP issued a negative opinion on arimoclomol, so the re-examination could still fail and delay or prevent access to a sizeable new geography. (BioSpace)
The US opportunity is still a small and developing market. Management estimates about 900 prevalent NPC patients, but only 300 to 350 are currently identified, so continued growth depends heavily on finding undiagnosed patients and converting them to treatment. (Fierce Pharma, StockAnalysis)
Celiprolol remains a slow, event-driven clinical bet rather than a near-term revenue source. Only three qualifying events had been confirmed by the end of the second quarter, versus 28 needed for an interim analysis and 46 for the full analysis, making timing and eventual success uncertain. (StockAnalysis, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2026.
ZVRA Financial Performance
Revenues and expenses
ZVRA Earnings Performance
Company profitability
Upcoming events
No upcoming events
ZVRA News
AllArticlesVideos
Funds containing ZVRA
AllUSDGBPEUR
Fund name | Fund size | $ZVRA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.04% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.04% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.